Drug Discovery World

JANUARY 19, 2023

Loreto Gesualdo, full Professor, Head of the Nephrology, Dialysis and Transplantation Unit, University of Bari Aldo Moro, Italy, and lead investigator of the RACERS study, stated: “There is a complete lack of treatment options for septic patients at high risk of developing acute kidney injury, a disease that in 2019 had an estimated 13.7

Drugs 130

Drugs Clinical Trials Trials Virus 130

Drug Discovery World

MAY 15, 2023

Kenneth Hitchner, Chairman, Board of Directors, Sphere Fluidics Hitchner has spent much of his 28-year career at Goldman Sachs in the biopharmaceutical and medical device sectors; a member of the Global Management committee and Chairman and CEO of Asia Pacific, excluding Japan, from 2013 to 2019.

Science 130

Science Laboratories Clinical Development Therapies 130

Drug Discovery World

SEPTEMBER 14, 2023

“This submission, and Janssen’s ongoing study of erdafitinib, reinforces our commitment to deliver much-needed targeted therapies in the areas of high unmet need, including for devastating diseases like metastatic UC,” said Kiran Patel, Vice President, Clinical Development, Solid Tumours, Janssen Research & Development, LLC.

Treatment 130

Treatment Clinical Pharmacology FDA Approval Therapies 130

The Pharma Data

DECEMBER 13, 2020

Our highly experienced teams in Singapore and the US span antibody discovery, pharmacology, production and clinical development. Together we aim to accelerate the journey of new drugs from concept to clinical care. 2019; 25: 4966–4972. For more information, visit tempus.com. [1] Clin Cancer Res.

Clinical Development 52

Clinical Development Clinical Trials Therapies Trials 52

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Drug Discovery World

FEBRUARY 12, 2024

Clinical impact of high-profile animal-based research reported in the UK national press. doi:10.1136/bmjos-2019-100039 Pound P. Drug discovery and development tomorrow – Changing the mindset. Drug discovery and development tomorrow – Changing the mindset. Clinical Development Success Rates 2006-2015.;

Animal Testing 147

Animal Testing Disease Trials Research 147

The Pharma Data

JULY 29, 2021

Kumquat brings together an accomplished team and distinguished scientific founder with a proven track record of innovative oncology drug discovery and development. The company was launched in 2019 and has raised over $100 million from OrbiMed, Sequoia Capital China, EcoR1, Lilly Asia Ventures, and Roche Venture Fund.

Small Molecule 52

Small Molecule Immune Response Research Laboratories Laboratories 52

The Pharma Data

DECEMBER 21, 2020

Legend will receive $75 million from J&J as a clinical development-based milestone payment, per a 2017 collaboration pact.

Therapies 40

Therapies Licensing Licensing FDA 40

The Pharma Data

JANUARY 4, 2021

Rothenberg took over as Pfizer CMO in January 2019, but spent more than 12 years in total working for the pharmaceutical giant. From 2016 to 2018, he served as chief development officer for oncology at Pfizer, where he was responsible for leading clinical research, development, and lifecycle management of all promising oncology products.

Pharma Companies 52

Pharma Companies Clinical Development Clinical Research International 52

The Pharma Data

DECEMBER 10, 2020

executive vice president of research and development. “We We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible.”. Safe Harbor Statement.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

The Pharma Data

NOVEMBER 23, 2020

The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. . .

Compliance 52

Compliance Licensing Licensing Clinical Trials 52

The Pharma Data

OCTOBER 31, 2020

With the IND approval in place, we are ready and eager to extend the clinical study of TG-1000 to the U.S. billion USD in 2019 and is estimated to reach 5.03 Currently the market is comprised primarily of the neuraminidase inhibitor oseltamivir and the newly developed endonuclease inhibitor baloxavir. in the near future.”

FDA Approval 52

FDA Approval FDA Virus Clinical Development 52

The Pharma Data

JANUARY 7, 2021

Cerecor intends to use the net proceeds of the offering for general corporate purposes and working capital, primarily to support the ongoing clinical development of key assets within its pipeline and for general and administrative expenses. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007.

Clinical Development 52

Clinical Development Disease FDA Approval Treatment 52

The Pharma Data

JANUARY 21, 2021

Securities and Exchange Commission (“SEC”) on November 27, 2019, amended on December 18, 2019 and declared effective on December 20, 2019 and an additional registration statement on Form S-3 (File No. The gross proceeds of the offering are expected to be approximately $100.0 333-235297) that was filed with the U.S.

Production 52

Production Clinical Development 52

Drug Target Review

AUGUST 24, 2023

She joined the company in November 2018 with more than 10 years of experience in drug discovery and non-clinical development of immunomodulatory drugs in the immuno-oncology space. 2019 May 22;10:1078. She has established a track record as a successful leader and entrepreneur in the biotech industry. Frontiers in Immunology.

Treatment 98

Treatment Therapies Clinical Development Cell Biology 98

Drug Discovery World

MARCH 29, 2023

Peter O’Donnell, Applied Clinical Trials’ Brussels Correspondent, summarises this as the EMA being tasked with creating a European network of patient representatives, academics, drug developers, investigators, and centres with expertise in the performance of studies in the paediatric population.

Clinical Trials 130

Clinical Trials Biosimilars Pharma Companies Production 130

The Pharma Data

JANUARY 3, 2021

InspirMed is a newly established subsidiary of TLC specializing in the development of inhalable liposome formulation programs, such as TLC19 for the treatment of Coronavirus disease 2019 (COVID-19) as well as other programs for severe acute and chronic pulmonary diseases.

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Trials Disease 52

The Pharma Data

JANUARY 25, 2021

. “This marks our second strategic agreement with Asieris, a well-run and well-capitalized company that is executing ahead of plan on the clinical development of Cevira ®, which we licensed to them in July 2019. ” About Photocure ASA.

Licensing 40

Licensing Licensing Clinical Development Pharmaceutical Companies 40

The Pharma Data

JANUARY 20, 2021

The securities are being offered pursuant to a registration statement that was filed with the Securities and Exchange Commission (“SEC”) on November 6, 2018, amended on February 6, 2019, and was declared effective on February 11, 2019.

Clinical Development 40

Clinical Development Therapies Science Drugs 40

PerkinElmer

JANUARY 7, 2022

The pharmaceutical industry is under huge pressure to address the high attrition rates in drug development. With around 90% of candidates failing during clinical development, 1 the process is not only long and risky, but also expensive for those involved. Sci Rep 9, 18911 (2019). References Hingorani, A.D.,

Drugs 52

Drugs Pharmacokinetics FDA Approval Drug Development 52

The Pharma Data

MARCH 2, 2021

This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. Financial terms of the new agreement are not disclosed.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

NIH Director's Blog: Drug Development

SEPTEMBER 26, 2019

Science Translational Medicine, 2019 Researchers continue to produce impressive miniature human tissues that resemble the structure of a range of human organs, including the livers, kidneys, hearts, and even the brain. 2019 Jun 19;11(497). [2] 2] Clinical development success rates for investigational drugs.

Drugs 72

Drugs Science Treatment Clinical Trials 72

The Pharma Data

DECEMBER 14, 2020

This grant will support Alume’s clinical development of its novel nerve illumination technology in surgery. Alume previously received a Phase I SBIR grant in 2019 from the NINDS to develop nerve illumination agents for surgical use. (Alume) announced today that it has been awarded a $2.5M

Clinical Trials 52

Clinical Trials Trials Clinical Development Pharmaceuticals 52

The Pharma Data

JANUARY 27, 2021

As a clinician, healthcare administrator, biotech entrepreneur and venture capital investor, Steve’s leadership and breadth of experience in the clinical development of cell and gene therapies will be invaluable to PlateletBio as we progress our cell therapy platform into the clinic later this year,” said Sam Rasty, Ph.D.,

Therapies 52

Therapies Engineering Clinical Development Disease 52

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, making it the first AI-generated target from the collaboration to enter the Company’s portfolio. . LONDON , Jan.

Disease 52

Disease Clinical Development Treatment Drug Development 52

The Pharma Data

OCTOBER 15, 2020

ASLAN believes ASLAN003 has the potential to bethe most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH enzyme than teriflunomide. In 2019, ASLAN completed a Phase 2 study testing ASLAN003 in AML. SINGAPORE, Oct.

Pharmaceuticals 40

Pharmaceuticals Cell Based Assays Clinical Development Treatment 40

The Pharma Data

JANUARY 24, 2021

Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. billion during 2019-2023 (Technavio 2019). References: Bailly, C.,

FDA 52

FDA Drugs Clinical Development Pharmaceutical Companies 52

Drug Discovery World

MAY 6, 2024

Amsterdam: The centre of European life sciences As a result of the UK withdrawing from the EU, in 2019 the EMA headquarters was moved from London to Amsterdam. Even before this, however, Amsterdam was established as an important centre for drug development. This article takes a closer look at several key clusters in the region.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

The Pharma Data

NOVEMBER 4, 2020

million as of December 31, 2019. Research and development expenses were $16.3 million for the same period in 2019. The increase in research and development expenses relates primarily to the ongoing Phase 2 clinical trial of CTP-692. million for the same period in 2019. 2019.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Small Molecule 52

The Pharma Data

JANUARY 25, 2021

. “ This marks our second strategic agreement with Asieris, a well-run and well-capitalized company that is executing ahead of plan on the clinical development of Cevira ®, which we licensed to them in July 2019. but with a healthcare system that is still developing. 2019; 76(5): 639-657 3 Sievert KD et al.

Clinical Development 40

Clinical Development Licensing Licensing Production 40

The Pharma Data

NOVEMBER 8, 2020

The resubmission came after a meeting with the FDA in February 2020 and addresses issues raised by the agency’s Complete Response Letter (CRL) in November 2019. “We The NDA was resubmitted on May 2020. We have been encouraged by our interactions with the FDA following our CRL and are pleased to resubmit our Zimhi NDA,” said Dennis J.

FDA 52

FDA Trials Pharmaceuticals Pharmacokinetics 52

The Pharma Data

OCTOBER 18, 2020

Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development. References: 1. European Medicines Agency. emc/medicine/34321.

Treatment 40

Treatment Clinical Development Therapies Production 40

The Pharma Data

NOVEMBER 23, 2020

At Ultimovacs, he will lead all business and corporate development efforts and continue to maintain and foster connections with leading biotechnology and pharmaceutical companies. “In Ton Berkien joins Ultimovacs with over 15 years of experience in strategic business development and corporate finance in the biopharmaceutical industry.

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

Metabolite Tales Blog

JANUARY 26, 2023

Likely linked to this are the scaffolds taken through to clinical developed, since a feature common to the vast majority of CYP2D6 substrates is a basic nitrogen atom and a planar aromatic ring that need to fit in a rather buried active site, compared to the larger and more flexible active site of CYP3A4. link] Maréchal et al.,

Small Molecule 52

Small Molecule FDA Approval FDA Drugs 52

The Pharma Data

OCTOBER 19, 2020

She is executive medical director of immunology clinical development for the pharmaceutical company AbbVie in North Chicago, Ill. “Upadacitinib has shown superiority to one of the current standard-of-care treatment options in the clinic for these difficult-to-treat patients,” Pangan said. ” Rinvoq received U.S.

Clinical Trials 52

Clinical Trials Drugs Trials Treatment 52

The Pharma Data

DECEMBER 29, 2020

The expansion of the eligible stocks of Hong Kong Stock Connect, will further optimize the interconnected, intercommunicated, and mutual development of the capital markets between Mainland China and Hong Kong. ” About Ascentage Pharma. Ascentage Pharma (6855.HK)

FDA 52

FDA Clinical Development Regulations Clinical Trials 52

The Pharma Data

DECEMBER 14, 2020

The shares of common stock described above are being offered by the Company pursuant to its automatically effective shelf registration statement previously filed with the SEC on September 5, 2019.

Clinical Trials 40

Clinical Trials Clinical Development Production Trials 40